Drugs / SYR-619
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00763347 | Nov 2006 → Feb 2007 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYR-619 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00763347 ↗ |
| Action | Inhibit | “SYR-619 is an inhibitor of the dipeptidyl peptidase IV enzyme.” NCT00763347 ↗ |
| Route | Oral | “SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.” NCT00763347 ↗ |